Lexeo Therapeutics, Inc. Common Stock

LXEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
2.70 USD
↘ 0.10 (3.57%)AT CLOSE (03:59 PM EDT)
2.71
↗ 0.01 (0.19%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
2.71
↗ 0.01 (0.19%)
🔴Market: CLOSED

Lexeo Therapeutics, Inc. Common Stock (LXEO) trades at $2.71 per share. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest LXEO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 26, 2026.

Open?$2.80
High?$2.83
Low?$2.68
Prev. Close?$2.80
Volume?1.2M
Avg. Volume?1.8M
VWAP?$2.71
Rel. Volume?0.66x
Bid / Ask
Bid?$2.33 × 100
Ask?$3.40 × 100
Spread?$1.07
Midpoint?$2.87
Valuation & Ratios
Market Cap?229.8M
Shares Out?82.0M
Float?76.6M
Float %?93.4%
P/E Ratio?N/A
P/B Ratio?0.98
EPS?-$1.06
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
59
Market Cap
229.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lexeotx.com
Listed
2023-11-03
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Phone: (212) 547-9879
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
95
Momentum?
77
Short Sent.?
44
Piotroski F-Score?0/9Weak
Altman Z-Score?4.33Safe
Confidence?43%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.91%Squeeze Risk
Short Interest?17.6M
Days to Cover?10.0
Free Float76.6M
Avg Daily Volume1.7M
Settlement Date2026-10-15
Financial Health
Current Ratio?13.89Strong
Quick Ratio?13.89Strong
Cash Ratio?5.92Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.98CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-37.1%WEAK▾
ROA?
S&P
3
-34.2%WEAK▾
Cash Flow & Enterprise
FCF?$-88698000
Enterprise Value?$137.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist